Results 221 to 230 of about 530,731 (290)

Bioorthogonal Chemistry in Neurobiology: From Imaging to Proteomics

ChemBioChem, Volume 27, Issue 20, 28 October 2026.
This review highlights emerging strategies for labeling neuronal proteins, enabling visualization and quantitative analysis of their expression, localization, and dynamics. By combining genetic code expansion (GCE), metabolic labeling, and click chemistry‐based labeling, these approaches provide powerful routes to study proteins in specific cells and ...
Neil Taylor, João de Sousa‐Lourenço, Ivana Nikić‐Spiegel   +2 more
wiley   +1 more source

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma. [PDF]

Blood Cancer J
Sharp J, Bhatta S, Huang JJ, Thomas CJ, Elghawy O, Fitzgerald L, Reef D, Teferra A, Voorhees TJ, Gupta S, Grover NS, Barta SK, Shadman M, Epperla N.   +13 more
europepmc   +1 more source

Development of a bispecific antibody that inhibits EGFR and B7H3 in NSCLC. [PDF]

Biomark Res
Zhi X, Wang J, Guo J, Luo L, Sun H, Li Y, Zhao Z, Wang C, Zhu L, Li X, Wang F, Li F, Yu K, Ren S.   +13 more
europepmc   +1 more source

B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer. [PDF]

Immunotargets Ther
Kielbik A, Bahlinger V, Schürch CM, Barcena ML, Vakhrusheva O, Thomas A, Tsaur I, Heitmann JS, Salih HR, Hagelstein I.   +9 more
europepmc   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz, Martin Ebinger, Michaela Döring, Markus Mezger, Ursula Holzer, Rupert Handgretinger, Peter Lang, Manon Queudeville   +7 more
wiley   +1 more source

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors. [PDF]

J Immunother Cancer
Rohrberg KS, Melero I, F Sanmamed M, Muñoz-Couselo E, Cervantes A, Gambardella V, Greillier L, Garrido P, Kim HR, Lee DH, Italiano A, Cassier PA, Hiret S, Deva S, Kim TM, Blumenschein GR, Løvendahl Eefsen R, Henick BS, Perro M, Umaña P, Peixoto A, Lauener L, Weber P, Seeber S, Klein C, Higgins B, Guidi M, Kraus D, Mücke M, Heichinger C, Tran VL, Schmid D, Michielin F, Liu T, McIntyre C, Kao H, Codarri Deak L, Markert C, Moreno V.   +38 more
europepmc   +1 more source

From Molecular Targets to Advanced Delivery Systems: Aptamers for Precision Ocular Therapeutics

Advanced Therapeutics, Volume 9, Issue 10, October 2026.
Aptamer‐based strategies are revolutionizing ocular disease management through highly specific molecular recognition of disease specific molecular targets. This review systematically integrates therapeutic aptamer sequences, diagnostic aptasensor platforms, and targeted delivery strategies, highlighting design principles, ocular bioavailability ...
Minal Thacker, Ka‐Ying Wong, Liping Zhou, Man‐Sau Wong, Juewen Liu   +4 more
wiley   +1 more source

A novel bispecific antibody targeting OX40L and TNFα for the targeted treatment of rheumatoid arthritis. [PDF]

Antib Ther
Zhang Q, Song S.
europepmc   +1 more source

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco, Stefania Bramanti, Paolo Corradini, Enrico Derenzini, Pier Luigi Zinzani   +4 more
wiley   +1 more source

Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis. [PDF]

MAbs
Sims GP, Scaletta L, Andrews J, Sims DA, Strain M, Sigurdardottir A, Kuriakose T, England E, Rajasinghe L, Jiang F, Xiong X, Neal F, Vinall L, Newton P, Boger E, Kim C, Dahlbäck H, Prothon S, Leander J, Darrah E, Collins M, Douglas G, White N, Day K, Vousden KA, Huntington CE, Close D.   +26 more
europepmc   +1 more source